Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more
Curative Biotechnology Inc (CUBT) - Total Liabilities
Latest total liabilities as of March 2025: $7.28 Million USD
Based on the latest financial reports, Curative Biotechnology Inc (CUBT) has total liabilities worth $7.28 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Curative Biotechnology Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Curative Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Curative Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Curative Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nuheara Ltd
AU:NUH
|
Australia | AU$7.91 Million |
|
Implanet SA
PA:ALIMP
|
France | €17.90 Million |
|
Electro-Sensors Inc
NASDAQ:ELSE
|
USA | $1.05 Million |
|
Indomobil Multi Jasa Tbk
JK:IMJS
|
Indonesia | Rp26.66 Trillion |
|
Pool Advista Indonesia Tbk
JK:POOL
|
Indonesia | Rp11.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM11.72 Million |
|
ADVFN Plc
PINK:AVFCF
|
USA | $1.35 Million |
|
NeuroMetrix Inc
NASDAQ:NURO
|
USA | $1.01 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Curative Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Curative Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Curative Biotechnology Inc (2013–2024)
The table below shows the annual total liabilities of Curative Biotechnology Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.08 Million | +23.15% |
| 2023-12-31 | $5.75 Million | -74.60% |
| 2022-12-31 | $22.62 Million | +20.48% |
| 2021-12-31 | $18.77 Million | +176.26% |
| 2020-12-31 | $6.80 Million | +1611.33% |
| 2019-12-31 | $397.10K | -45.93% |
| 2018-12-31 | $734.36K | +2.23% |
| 2017-12-31 | $718.33K | +2.28% |
| 2016-12-31 | $702.29K | +2.20% |
| 2015-12-31 | $687.16K | -28.50% |
| 2014-12-31 | $960.99K | +3.04% |
| 2013-12-31 | $932.66K | -- |